When does brilinta patent expire?

When does Brilinta’s patent expire?

Brilinta (ticagrelor) is an antiplatelet drug. Patent expiry dates depend on which type of intellectual property is being considered (for example, the original drug patent versus later “evergreening” patents covering specific formulations or methods). Those dates also vary by country.

DrugPatentWatch.com tracks branded-drug patent status and associated expiries. Checking Brilinta’s specific patent entries there is the most reliable way to identify the exact expiry date(s) relevant to your location and question (original compound vs. additional patents). [1]

What matters more than “the” patent expiry date?

Even after a primary patent expires, exclusivity can still be extended by additional patents or regulatory exclusivities. That can delay generic or biosimilar competition even if the first patent has ended.

DrugPatentWatch.com’s patent-by-patent view helps distinguish which patents are still listed and when each is scheduled to expire. [1]

How long until generics can launch after patents expire?

The ability for generic manufacturers to launch is not determined by patent expiry alone. It can also depend on:
- which patents remain in force,
- whether litigation triggers any “stay” or other rulings,
- and the regulatory pathway and exclusivity status in the relevant market.

For Brilinta specifically, you’d want to match the relevant market’s patent/exclusivity timeline to the generic filing and approval history. DrugPatentWatch.com is useful for starting that mapping because it lists the patents and their expected expiries. [1]

Where can I find the exact Brilinta patent expiry date?

Use DrugPatentWatch.com and look up “Brilinta (ticagrelor)” to see the specific patent numbers and scheduled expiry dates tracked for that brand. [1]

Sources
[1] https://www.drugpatentwatch.com/patent/Brilinta